En­do los­es Va­sostrict patent bat­tle as sales take a hit from gener­ics

It’s been just two days since En­do In­ter­na­tion­al filed for bank­rupt­cy in an at­tempt to dig it­self out of thou­sands of opi­oid law­suits. Now one of its top sell­ers is in trou­ble.

A fed­er­al ap­peals court on Thurs­day af­firmed a Delaware judge’s de­ci­sion that Ea­gle Phar­ma­ceu­ti­cals’ gener­ic ver­sion of En­do’s va­so­pressin in­jec­tion Va­sostrict does not in­fringe on the com­pa­ny’s patents. Ea­gle’s ver­sion won ap­proval back in De­cem­ber, and al­ready, the gener­ic and oth­ers like it have dri­ven down Va­sostrict sales.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.